Bayer and Dewpoint Therapeutics sign Licensing Agreement for Heart Disease Program
Bayer obtains global license to develop and commercialize disease-modifying treatment specifically for dilated cardiomyopathy ( DCM ) patients characterized by specific mutations Post-licensing, companies will continue to collaborate on cardiovascular and renal programs
| Ticker |
Sentiment |
Impact |
|
META
|
Neutral
|
4 %
|
|
TRMNF
|
Neutral
|
4 %
|
|
NVO
|
Neutral
|
4 %
|
|
EVO
|
Neutral
|
4 %
|
